Friday 6-20-2014 Gilead Sciences (GILD) $GILD open
Post# of 162
Posted On: 06/20/2014 11:20:13 PM
Friday 6-20-2014 Gilead Sciences (GILD) $GILD opened at 80.14 hitting the high price of 81.55 and a day low of 79.68 with a total volume of 17,946,359. GILD had a previous close of 79.78 and has been seeing an average volume of 10,486,800.
Overall Average: 32% Buy
Recent stock forum discussions about GILD http://investorshangout.com/search?q=GILD&...mp;yt0=Go!
Final Glance: Biotechnology companies
AP - Fri Jun 20, 5:05PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading: (full story)
Is Gilead Sciences, Inc. Destined for Greatness?
Alex Planes, The Motley Fool - Motley Fool - Fri Jun 20, 5:00PM CDT
Investors love stocks that consistently beat the Street without getting ahead of their fundamentals and risking a meltdown. The best stocks offer sustainable market-beating gains, with robust and improving financial metrics that support strong price... (full story)
AstraZeneca's Naloxegol Data Published - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 20, 5:00PM CDT
AstraZeneca (AZN) announced that data related to its opioid-induced constipation candidate, naloxegol, was published in the New England Journal of Medicine. (full story)
Alnylam-TAP Collaborate for AAT Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 20, 3:45PM CDT
Alnylam Pharmaceuticals (ALNY) inked a collaboration deal with TAP for the continued development of ALN-AAT. (full story)
OncoMed's OMP-54F28 on Partial Clinical Hold - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 20, 2:50PM CDT
OncoMed Pharmaceuticals Inc. (OMED) recently suffered another setback when the FDA had placed a partial clinical hold on phase I clinical trials of another pipeline candidate, OMP-54F28. (full story)
Merge Healthcare: Updated Research Report - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 20, 1:55PM CDT
On Jun 20, 2014, we issued an updated research report on Merge Healthcare Incorporated (MRGE). (full story)
Illumina: Updated Research Report - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 20, 1:30PM CDT
On Jun 20, 2014, we issued an updated research report on life sciences company Illumina Inc. (ILMN). (full story)
Midday Glance: Biotechnology companies
AP - Fri Jun 20, 12:26PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.: (full story)
Achillion Could Win Idenix's Mystery Suitor: Analyst
at Investor's Business Daily - Fri Jun 20, 11:44AM CDT
Hot biotech stock Achillion Pharmaceuticals (ACHN) was up 2%, near 8.20, in midday trading in the stock market today after an analyst found more support for its prospects as a buyout candidate. R. W. Baird's Brian Skorney noted that Merck's (MRK)... (full story)
Better Stock Today Challenge: Gilead vs. DistributionNow
David Williamson and Joel South, The Motley Fool - Motley Fool - Fri Jun 20, 11:40AM CDT
In the spirit of World Cup competition, we're holding our own tournament in search of the Better Stock Today. We're pitting 32 companies against each other and you, the reader, will determine the winner. Today it's the round of 16, and Gilead ... (full story)
Celgene Rises on Yet Another Stock Split - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 20, 10:30AM CDT
Shares of Gelgene (CELG) gained following the approval of a stock split. (full story)
Gilead Sciences (GILD) Crosses Pivot Point Resistance at $80.56
Comtex SmarTrend(R) - Fri Jun 20, 10:12AM CDT
Shares of Gilead Sciences (NASDAQ:GILD) have bullishly opened above the pivot of $79.72 today and have reached the first resistance level of $80.56. Should the shares continue to rise, the resistance pivots of $81.34 and $82.96 will be of interest. (full story)
Cubist Gets Priority Review from FDA for Antibiotic Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 20, 10:00AM CDT
The FDA will review Cubist's (CBST) ceftolozane/tazobactam on a priority basis . (full story)
Early Glance: Biotechnology companies
AP - Fri Jun 20, 9:35AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.: (full story)
'Mad Money' Lightning Round: Buy, Buy, Buy Stryker
at The Street - Fri Jun 20, 5:00AM CDT
Cramer prefers Celgene over Gilead Sciences, Palo Alto Networks over OSI Systems and is discouraged by IBM. (full story)
Jim Cramer's 'Mad Money' Recap: Management Matters, Not the Fed
at The Street - Thu Jun 19, 6:57PM CDT
People obsessed with the Fed have kept you out of the market, Cramer said, and the Fed's bond buyback tapering is simply not having an impact. (full story)
Protalix Drug in Phase IIa Study for Gaucher Disease - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 19, 5:15PM CDT
Protalix BioTherapeutics, Inc. (PLX) has enrolled the first patient in a phase IIa study on PRX-112 (oral GCD) for the treatment of Gaucher disease. (full story)
BioLineRx to Commence BL-8040 Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 19, 5:10PM CDT
BioLineRx Ltd. (BLRX) announced that the Israeli Ministry of Health informed the company that it can start a phase I study on its oncology candidate, BL-8040. (full story)
Valeant Launches Hostile Bid for Allergan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 19, 4:50PM CDT
Valeant Pharmaceuticals International, Inc. (VRX) announced that it has commenced an exchange offer for the common stock of Allergan, Inc (AGN). (full story)
Overall Average: 32% Buy
Recent stock forum discussions about GILD http://investorshangout.com/search?q=GILD&...mp;yt0=Go!
Final Glance: Biotechnology companies
AP - Fri Jun 20, 5:05PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading: (full story)
Is Gilead Sciences, Inc. Destined for Greatness?
Alex Planes, The Motley Fool - Motley Fool - Fri Jun 20, 5:00PM CDT
Investors love stocks that consistently beat the Street without getting ahead of their fundamentals and risking a meltdown. The best stocks offer sustainable market-beating gains, with robust and improving financial metrics that support strong price... (full story)
AstraZeneca's Naloxegol Data Published - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 20, 5:00PM CDT
AstraZeneca (AZN) announced that data related to its opioid-induced constipation candidate, naloxegol, was published in the New England Journal of Medicine. (full story)
Alnylam-TAP Collaborate for AAT Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 20, 3:45PM CDT
Alnylam Pharmaceuticals (ALNY) inked a collaboration deal with TAP for the continued development of ALN-AAT. (full story)
OncoMed's OMP-54F28 on Partial Clinical Hold - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 20, 2:50PM CDT
OncoMed Pharmaceuticals Inc. (OMED) recently suffered another setback when the FDA had placed a partial clinical hold on phase I clinical trials of another pipeline candidate, OMP-54F28. (full story)
Merge Healthcare: Updated Research Report - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 20, 1:55PM CDT
On Jun 20, 2014, we issued an updated research report on Merge Healthcare Incorporated (MRGE). (full story)
Illumina: Updated Research Report - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 20, 1:30PM CDT
On Jun 20, 2014, we issued an updated research report on life sciences company Illumina Inc. (ILMN). (full story)
Midday Glance: Biotechnology companies
AP - Fri Jun 20, 12:26PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.: (full story)
Achillion Could Win Idenix's Mystery Suitor: Analyst
at Investor's Business Daily - Fri Jun 20, 11:44AM CDT
Hot biotech stock Achillion Pharmaceuticals (ACHN) was up 2%, near 8.20, in midday trading in the stock market today after an analyst found more support for its prospects as a buyout candidate. R. W. Baird's Brian Skorney noted that Merck's (MRK)... (full story)
Better Stock Today Challenge: Gilead vs. DistributionNow
David Williamson and Joel South, The Motley Fool - Motley Fool - Fri Jun 20, 11:40AM CDT
In the spirit of World Cup competition, we're holding our own tournament in search of the Better Stock Today. We're pitting 32 companies against each other and you, the reader, will determine the winner. Today it's the round of 16, and Gilead ... (full story)
Celgene Rises on Yet Another Stock Split - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 20, 10:30AM CDT
Shares of Gelgene (CELG) gained following the approval of a stock split. (full story)
Gilead Sciences (GILD) Crosses Pivot Point Resistance at $80.56
Comtex SmarTrend(R) - Fri Jun 20, 10:12AM CDT
Shares of Gilead Sciences (NASDAQ:GILD) have bullishly opened above the pivot of $79.72 today and have reached the first resistance level of $80.56. Should the shares continue to rise, the resistance pivots of $81.34 and $82.96 will be of interest. (full story)
Cubist Gets Priority Review from FDA for Antibiotic Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 20, 10:00AM CDT
The FDA will review Cubist's (CBST) ceftolozane/tazobactam on a priority basis . (full story)
Early Glance: Biotechnology companies
AP - Fri Jun 20, 9:35AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.: (full story)
'Mad Money' Lightning Round: Buy, Buy, Buy Stryker
at The Street - Fri Jun 20, 5:00AM CDT
Cramer prefers Celgene over Gilead Sciences, Palo Alto Networks over OSI Systems and is discouraged by IBM. (full story)
Jim Cramer's 'Mad Money' Recap: Management Matters, Not the Fed
at The Street - Thu Jun 19, 6:57PM CDT
People obsessed with the Fed have kept you out of the market, Cramer said, and the Fed's bond buyback tapering is simply not having an impact. (full story)
Protalix Drug in Phase IIa Study for Gaucher Disease - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 19, 5:15PM CDT
Protalix BioTherapeutics, Inc. (PLX) has enrolled the first patient in a phase IIa study on PRX-112 (oral GCD) for the treatment of Gaucher disease. (full story)
BioLineRx to Commence BL-8040 Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 19, 5:10PM CDT
BioLineRx Ltd. (BLRX) announced that the Israeli Ministry of Health informed the company that it can start a phase I study on its oncology candidate, BL-8040. (full story)
Valeant Launches Hostile Bid for Allergan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 19, 4:50PM CDT
Valeant Pharmaceuticals International, Inc. (VRX) announced that it has commenced an exchange offer for the common stock of Allergan, Inc (AGN). (full story)
(0)
(0)